Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
NUTLEY, N.J. and BASEL, Switzerland, Jan. 2 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly-owned subsidiary 900 North Point Acquisition...
MONTVALE, N.J., Dec. 24 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has dosed the first patient in its Phase 2 clinical study of the effect of...
MONTVALE, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced positive results from its Phase 1 program for R4996/MEM 63908, a partial agonist of...
Study to Evaluate Proof-of-Concept for Company's Lead PDE4 Inhibitor MONTVALE, N.J., Dec. 18 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has...
MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that the NASDAQ Listing and Hearing Review Council has determined that the Company...
- Company Granted Stay of Delisting by NASDAQ Review Council - MONTVALE, N.J., Dec. 3 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that, on December 3...
DALLAS, Nov. 26 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting:...
NUTLEY, N.J. and MONTVALE, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Roche and Memory Pharmaceuticals (NASDAQ:MEMY) today announced that the two companies have signed a definitive merger agreement...
-Triggers $5 Million Payment from Roche- MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (NASDAQ:MEMY) today announced that it has achieved the enrollment goal for...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
